Clinical Trial Update: Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of interleukin-2 and bryostatin-1 in patients with advanced renal cell carcinoma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 2 | Status: COMPLETED